Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -131.01M | -117.50M | -108.12M | -162.25M | -171.90M |
| Total Depreciation and Amortization | 18.17M | 19.67M | 19.48M | 21.04M | 23.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.45M | 24.54M | 31.89M | 50.15M | 36.48M |
| Change in Net Operating Assets | -18.56M | -7.81M | 10.68M | -26.30M | 35.15M |
| Cash from Operations | -105.95M | -81.10M | -46.07M | -117.36M | -76.42M |
| Capital Expenditure | -44.00K | -258.00K | -1.24M | -243.00K | -3.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | 0.00 | 0.00 |
| Other Investing Activities | -1.92M | -80.00K | 0.00 | -2.31M | -2.66M |
| Cash from Investing | -1.96M | -338.00K | -1.24M | -2.55M | -5.81M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.25M | -2.21M | -2.17M | -2.13M | -2.08M |
| Issuance of Common Stock | -- | -- | 134.17M | 253.47M | 100.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 984.00K | -1.26M | 0.00 | 0.00 | -257.00K |
| Cash from Financing | -1.27M | -3.47M | 132.01M | 251.34M | 97.66M |
| Foreign Exchange rate Adjustments | 813.00K | -3.83M | 2.09M | 1.87M | 9.26M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.36M | -88.74M | 86.78M | 133.30M | 24.69M |